Theranostics — which combines molecular imaging with targeted therapy — is quickly becoming a significant innovation in cancer care, offering more precise treatment with fewer side effects. GE Healthcare expects the field to grow rapidly over the next decade, as long as hospitals can continue to invest in the imaging and software infrastructure needed to scale these therapies.
The post Theranostics Could Transform Cancer Care, GE Healthcare Leader Says appeared first on MedCity News.
